CONTRACTING ORGANIZATION: Rutgers, the State University of New Jersey New Brunswick, NJ 08901

Similar documents
CONTRACTING ORGANIZATION: University of California Lawrence Berkeley National Laboratory Berkeley, CA 94720

AWARD NUMBER: W81XWH TITLE: Androgen Deprivation Therapy and Cognitive Impairment. PRINCIPAL INVESTIGATOR: Robert N. Pechnick, Ph.D.

CONTRACTING ORGANIZATION: Regents of the University of Michigan Ann Arbor, MI 48109

CONTRACTING ORGANIZATION: Oregon Health & Science University Portland OR 97239

Sphingosine-1-Phosphate Receptor Subtype 3: A Novel Therapeutic Target of K-Ras Mutant Driven Non-Small Cell Lung Carcinoma

AWARD NUMBER: W81XWH TITLE: Gulf War Illness as a Brain Autoimmune Disorder. PRINCIPAL INVESTIGATOR: Apostolos Georgopoulos, MD, PhD

U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

Fort Detrick, Maryland

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

TITLE: Dietary Genistein and Prostate Cancer Chemoprevention

TITLE: New Advanced Technology to Improve Prediction and Prevention of Type 1 Diabetes

CONTRACTING ORGANIZATION: North Eastern Ohio Universities Rootstown OH 44202

U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

TITLE: Neural Protein Synuclein (SNCG) in Breast Cancer Progression

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

TITLE: Functional Genetics for Predisposition to Development of Type 2 Diabetes in Obese Individuals. PRINCIPAL INVESTIGATOR: Assia Shisheva

TITLE: Proteomic Mapping of the Immune Response to Gluten in Children with Autism

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

CONTRACTING ORGANIZATION: Western Institute For Biomedical Research Salt Lake City, UT

TITLE: Properties of Leukemia Stem Cells in a Novel Model of CML Progression to Lymphoid Blast Crisis

AWARD NUMBER: W81XWH TITLE: Treatment of Pain and Autonomic Dysreflexia in Spinal Cord Injury with Deep Brain Stimulation

TITLE: Genes Associated with Food Allergy and Eosinophilic Esophagitis

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

TITLE: Treatment of Dengue Virus Infection with Repurposed Pharmaceuticals that Inhibit Autophagy

AD (Leave blank) Award Number: W81XWH TITLE: Targeting Autophagy for the Treatment of TSC and LAM. PRINCIPAL INVESTIGATOR: Elizabeth Henske

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

TITLE: Identification of New Serum Biomarkers for Early Breast Cancer Diagnosis and Prognosis Using Lipid Microarrays.

TITLE: Development of a Blood-Based Biomarker Panel for Indeterminate Lung Nodules

CONTRACTING ORGANIZATION: Cold Spring Harbor Laboratory Cold Spring Harbor, NY 11724

CONTRACTING ORGANIZATION: Joan & Sanford I. Weill Medical College of Cornell University New York, NY 10065

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

CONTRACTING ORGANIZATION: Johns Hopkins Bloomberg School of Public Health

TITLE: Evaluation of DNA Methylation as a Target for Intraductal Therapy for Ductal Carcinoma in Situ of the Breast

TITLE: Oxidative Stress, DNA Repair and Prostate Cancer Risk. PRINCIPAL INVESTIGATOR: Hua Zhao, Ph.D.

Award Number: W81XWH TITLE: Global Positioning Systems (GPS) Technology to Study Vector-Pathogen-Host Interactions

TITLE: Prevention and Treatment of Neurofibromatosis Type 1-Associated Malignant Peripheral Nerve Sheath Tumors

TITLE: 64Cu-DOTA-trastuzumab PET imaging in women with HER2 overexpressing breast cancer

Page 1 AWARD NUMBER: W81XWH TITLE: A Novel Pleiotropic Anti-Inflammatory Drug to Reduce ARDS Incidence. PRINCIPAL INVESTIGATOR: Gary Nieman

Award Number: W81XWH

TITLE: Role of ADAM15 in Tumor/Endothelial Interactions Prostate Cancer Regression

TITLE: Targeting the Immune System s Natural Response to Cell Death to Improve Therapeutic Response in Breast Cancers

TITLE: Overcoming Resistance to Inhibitors of the Akt Protein Kinase by Modulation of the Pim Kinase Pathway

AD (Leave blank) TITLE: Proteomic analyses of nipple fluid for early detection of breast cancer

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

TITLE: Central Tolerance Blockade to Augment Checkpoint Immunotherapy in Melanoma

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

TITLE: Demonstrating the Efficacy of Group Prolonged Exposure Treatment of PTSD in OEF/OIF/OND Male Veterans

Award Number: W81XWH TITLE: Dietary Fish Oil in Reducing Bone Metastasis of Breast Cancer

CONTRACTING ORGANIZATION: Mount Sinai School of Medicine New York, New York

The Chancellor, Masters and Scholars of the University of Cambridge, Clara East, The Old Schools, Cambridge CB2 1TN

Award Number: W81XWH

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

CONTRACTING ORGANIZATION: Sloan-Kettering Institute for Cancer Research New York, NY 10021

TITLE: Harnessing GPR17 Biology for Treating Demyelinating Disease

CONTRACTING ORGANIZATION: Fred Hutchinson Cancer Research Center Seattle, WA 98109

TITLE: Inhibitors of Histone Deacetylases for Radiosensitization of Prostate Cancer

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

TITLE: Long Term Outcomes of BRCA1/BRCA2 Mutation Testing. CONTRACTING ORGANIZATION: Georgetown University Washington, DC

TITLE: Enhancing the Anti-Tumor Activity of ErbB Blockers with Histone Deaccetylase (HDAC) Inhibition in Prostate Cancer Cell Lines

Approved for public release; distribution unlimited

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

La Jolla, CA Approved for Public Release; Distribution Unlimited

CONTRACTING ORGANIZATION: The Chancellor, Masters and Scholars of the University of Cambridge, Clara East, The Old Schools, Cambridge CB2 1TN

TITLE: Selective Oncolytic Therapy for Hypoxic Breast Cancer Cells. CONTRACTING ORGANIZATION: Ordway Research Institute Albany, New York 12208

CONTRACTING ORGANIZATION: Cleveland Clinic Foundation Cleveland, OH 44195

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

Award Number: W81XWH TITLE: A Novel Membrane-Permeable, Breast-Targeting, Pro-Apoptotic Peptide for Treatment of Breast Cancer

TITLE: Maximizing Energy After Traumatic Brain Injury: A Novel Intervention

Award Number: W81XWH TITLE: Characterizing an EMT Signature in Breast Cancer. PRINCIPAL INVESTIGATOR: Melanie C.

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

TITLE: Prostate Expression Databases: Gene Expression Resources for Comparative Studies of Prostate Carcinogenesis

Promote Adjustment during Reintegration following Deployment

TITLE: Effects of Tobacco Smoke (TS) on growth of clear cell renal cell carcinoma (ccrcc)

TITLE: Induction of Ephs/Ephrins-Mediated Tumor Cells-Endothelial Cells Repulsion as an Anti-Cancer Therapeutic Approach

TITLE: Responsiveness of a Neuromuscular Recovery Scale for Spinal Cord Injury: Inpatient and Outpatient Rehabilitation

TITLE: Investigation of the Akt/PKB Kinase in the Development of Hormone-Independent Prostate Cancer

TITLE: MicroRNA in Prostate Cancer Racial Disparities and Aggressiveness

Award Number: W81XWH TITLE: Regenerative Stem Cell Therapy for Breast Cancer Bone Metastasis

Detection of Prostate Cancer Progression by Serum DNA Integrity

TITLE: Harnessing GPR17 Biology for Treating Demyelinating Disease

CONTRACTING ORGANIZATION: University of Texas M.D. Anderson Cancer Center Houston, TX 77030

TITLE: Interchromosomal Associations that Alter NF1 Gene Expression Can Modify Clinical Manifestations of Neurofibromatosis 1. Palo Alto, CA 94304

TITLE: Investigating the Role of TBX2 in the Inhibition of Senescence in Prostate Cancer

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

TITLE: Post-Traumatic Headache and Psychological Health: Mindfulness Training for Mild Traumatic Brain Injury

TITLE: Role of CDK5 as a Tumor Suppressor Gene in Non-Small Cell Lung Cancer

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, MD

Approved for public release; distribution unlimited

TITLE: Adipose Estrogen and Increased Breast Cancer Risk in Obesity: Regulation by Leptin and Insulin

CONTRACTING ORGANIZATION: UNIVERSITY OF ILLINOIS Chicago, IL 60612

TITLE: Prazosin for Treatment of Patients With PTSD and Comorbid Alcohol Dependence

TITLE: A Tissue Engineering Approach to Study the Progression of Breast Tumor Metastasis in Bone

TITLE: The Role of HOX Proteins in Androgen-Independent Prostate Cancer

TITLE: Mission Connect Mild TBI Translational Research Consortium. U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

Transcription:

AWARD NUMBER: W81XWH-16-1-0415 TITLE: Cell Type-Specific Contributions to the TSC Neuropathology PRINCIPAL INVESTIGATOR: Gabriella D Arcangelo CONTRACTING ORGANIZATION: Rutgers, the State University of New Jersey New Brunswick, NJ 08901 REPORT DATE: August 2017 TYPE OF REPORT: Annual PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012 DISTRIBUTION STATEMENT: Approved for Public Release; Distribution Unlimited The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE Form Approved OMB No. 0704-0188 Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS. 1. REPORT DATE 2. REPORT TYPE 3. DATES COVERED August 2017 Annual 1 Aug 2016-31 Jul 2017 4. TITLE AND SUBTITLE Cell Type-Specific Contributions to the TSC Neuropathology 5a. CONTRACT NUMBER 5b. GRANT NUMBER W81XWH-16-1-0415 5c. PROGRAM ELEMENT NUMBER 6. AUTHOR(S) Gabriella D Arcangelo 5d. PROJECT NUMBER 5e. TASK NUMBER 5f. WORK UNIT NUMBER E-Mail: darcangelo@dls.rutgers.edu 7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) 8. PERFORMING ORGANIZATION REPORT NUMBER Rutgers, The State University Of New Jersey 3 Rutgers Plza, New Brunswick NJ 08901-8559 9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) 10. SPONSOR/MONITOR S ACRONYM(S) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012 11. SPONSOR/MONITOR S REPORT NUMBER(S) 12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited 13. SUPPLEMENTARY NOTES 14. ABSTRACT Mutations in the human TSC2 gene cause tuberous sclerosis complex (TSC), a developmental disorder characterized by tumor susceptibility and neurological manifestations. To better understand the disease we generated an animal model in which the mouse Tsc2 gene is disrupted exclusively in excitatory neurons of the forebrain. We plan to investigate how heterozygous and homozygous Tsc2 mutations affect the development of mutant excitatory neurons as well as other surrounding brain cells, in vivo and in vitro. During this first year of support we primarily focused on Major Task 1: In vivo characterization of heterozygous and homozygous NEX-Tsc2 mice. Specifically, we performed Subtask 1: Animal breeding for in vivo studies, and nearly completed Subtask 3: Analysis of neuronal development and synaptogenesis. We studied the effects of Tsc2 mutations on neuronal development and found that heterozygous loss of Tsc2 in the forebrain has no effect, whereas homozygous loss disrupts the maturation of excitatory neurons. 15. SUBJECT TERMS Tuberous Sclerosis Complex, animal model, TSC2 16. SECURITY CLASSIFICATION OF: U a. REPORT Unclassified b. ABSTRACT Unclassified c. THIS PAGE Unclassified 17. LIMITATION OF ABSTRACT 18. NUMBER OF PAGES Unclassified 8 19a. NAME OF RESPONSIBLE PERSON USAMRMC 19b. TELEPHONE NUMBER (include area code) Standard Form 298 (Rev. 8-98) Prescribed by ANSI Std. Z39.18

Table of Contents Page 1. Introduction. 4 2. Keywords. 4 3. Accomplishments..... 4 4. Impact... 7 5. Changes/Problems.... 7 6. Products.... 7 7. Participants & Other Collaborating Organizations 7 8. Special Reporting Requirements 8 9. Appendices None

1. Introduction Mutations in the TSC2 gene cause tuberous sclerosis complex (TSC), a developmental disorder characterized by tumor susceptibility in multiple organs and frequent neurological manifestations, such as seizures, intellectual disability, and autism. There is currently no cure for TSC, although significant progress has been made in recent years in managing some of the clinical traits, particularly tumor growth and epilepsy. However, much remains to be done to relieve the burden of epilepsy and cognitive problems, such as intellectual disability and autism. In line with the mission of TSCRP, the goal of this research is to improve our understanding of the pathogenesis of TSC, focusing on the cellular and molecular mechanisms that lead to the development of neurological symptoms. We believe that this basic knowledge can be translated into better treatments, and can ultimately improve the lives of TSC patients. We hypothesized that heterozygous mutations in the TSC2 gene disrupt the normal development and function of excitatory neurons without affecting their size. Homozygous loss-of-function mutations, on the other hand, not only profoundly alter their size and intrinsic development, but also disrupt cell-cell communication with other cell types. These non cell-autonomous mechanisms exacerbate defects in synaptic function and cognition, and possibly contribute to the formation of cortical tubers and tumors in the TSC brain. 2. Keywords Tuberous Sclerosis Complex, animal model, TSC2 3. Accomplishments Major goals of the project The overall goal of this study is to define the cellular abnormalities of excitatory neurons that are deficient in TSC2 activity, and to understand how they impact the development of other neuronal and glial subtypes in the cerebral cortex. For our study we utilize NEX-Tsc2, a conditional Tsc2 knock out mouse line in which gene deletion occurs specifically in embryonic forebrain excitatory neurons, the most abundant cell type in the developing cerebral cortex. We proposed to characterize the neurodevelopmental defects of heterozygous and homozygous NEX-Tsc2 mice, including cell autonomous abnormalities in the migration and growth of excitatory neurons, as well as non-cell autonomous effects on inhibitory neurons and non-neuronal cell types. In collaboration with Dr. Anne Anderson, we also planned to use video-eeg recordings to determine whether heterozygous and homozygous NEX-Tsc2 mice exhibit seizures or increased susceptibility to chemoconvulsants. Our proposed work includes in vivo studies (Specific Aim1), some of which were performed during this period, and in vitro culture studies (Specific Aim 2), which will be performed as planned in upcoming years of support. As detailed in the SOW, during this initial period of support we focused on Major Task 1: In vivo characterization of heterozygous and homozygous NEX-Tsc2 mice, corresponding to Specific Aim 1 of the research proposal. Accomplishments under these goals As per Subtask 1: Animal breeding for in vivo studies, we generated experimental NEX- Tsc2 mice by breeding Cre +/+ ;Tsc2 flox/wt mice with heterozygous mice Cre -/- ;Tsc2 flox/wt. This breeding strategy generated 100% Cre +/- mice that were either wild type (WT = 4

Tsc2 wt/wt ), heterozygous (HET = Tsc2 fl/wt ) or homozygous (KO = Tsc2 fl/fl ) for Tsc2. Pups were born at the expected Mendelian ratio (25% WT, 50% HET, and 25% KO). As expected HET mice appeared indistinguishable from WT controls, whereas KO mutant mice appeared runt and some died prematurely at approximately 12-15 days after birth (P12-15). Despite some mortality, we were able to obtain 5 sets of P16 mice of each genotype (n= 5 WT, HET and KO) for our analysis. First, we measured the pups body weight, and second, we euthanized them and dissected the brain to measure the weight of this organ. Statistical analysis was performed using the GraphPad Prism 7 software (one way ANOVA followed by Dunnett's multiple comparisons test). The data show that HET pups were similar to WT controls, but KO pups were significantly smaller. Similarly, the brain of HET pups was similar to that of WT controls, whereas the brain of KO pups was slightly but significantly smaller than WT. 10 BODY WEIGHT (g) **** BRAIN WEIGHT (g) * 8 0.4 6 0.3 4 0.2 2 0.1 0 WT vs. KO: p =001 WT vs. KO: p =2674 To maintain the colony and regenerate breeder mice of the appropriate genotype we also interbred separately Cre +/+ ;Tsc2 flox/wt mice as well as Cre -/- ;Tsc2 flox/wt and select Tsc2 flox/wt from each progeny. These breeders were regenerated twice per year to ensure fertility. As per Subtask 3: Analysis of neuronal development and synaptogenesis, we further dissected the cerebral cortex from P16 brains, prepared protein lysates and performed Western blot analysis using antibodies against axon, dendrite and synaptic markers. As a genotype control we analyzed the expression of Tsc2. Specific proteins were detected using the quantitative LI-COR Odyssey Fc imaging system. Blots will be stained with REVERT Total Protein Stain (Li-COR) to control for protein loading, followed by primary antibodies and secondary antibodies conjugated to near-infrared fluorophores (Li-COR). Statistical analysis was performed as described above. The data plotted below show that there is no significant difference between genotypes regarding the expression levels of a dendrite marker (Map2), axon markers (TuJ1, Tau and NFH), a general presynaptic marker (Syn= synatophysin) or an excitatory postsynaptic marker (PSD95). However, there was a significant decrease in the expression of the inhibitory postsynaptic marker Gephryn in KO samples, and a marginal decrease in HET samples as well. These results suggest that Tsc2 deficiency in excitatory neurons results in a specific deficit in the formation of inhibitory synapses. 5

Tsc2/Revert Licor Map2/Revert Licor **** WT vs KO, p=001 Tuj1/Revert Licor WT vs. KO: p =0.8085 Tau/Revert Licor WT vs. KO: p =0.9731 NFH/Revert Licor WT vs. KO: p =9816 Syn/Revert Licor WT vs. KO: p =0.4647 PSD95/Revert Licor Gephryn/Revert Licor * WT vs. KO: p =8175 WT vs. KO: p =2979 Opportunities for training and professional development Results disseminated Plan for next reporting period 6

Next, we will perform Western blot analysis of synaptosomal fractions and immunofluorescence analysis of additional P16 NEX-Tsc2 mice as described in Subtask 3 to confirm our preliminary findings. Furthermore, we will perform Subtask 2: Analysis of neuronal migration in the cerebral cortex, Subtask 4: Analysis of non-cell autonomous differentiation and signaling defects, Subtask 5: Analysis of non-cell autonomous effects on proliferation and cell death. Thus we will complete Major Task 1: In vivo characterization of heterozygous and homozygous NEX-Tsc2 mice. Depending on the novelty of the findings we may reach the first milestone and submit a Manuscript on intrinsic neuronal abnormalities in Tsc2 mutants for publication. 4. Impact Impact on the development of the principal discipline of the project Our preliminary findings suggest that inhibitory synapses may be disrupted as a consequence of Tsc2 deficiency in NEX-Tsc2 HET and KO mice. If confirmed, this would be a novel and exciting result, pointing to a functional abnormality in synaptogenesis that may cause disinhibition of excitatory neurons in TSC patients as well as animal models. The deficit in the formation of inhibitory synapses could underlie the excessive neuronal activation and the seizures that are frequently associated with TSC. Impact on other disciplines Impact on technology transfer impact on society 5. Changes/problems 6. Products 7. Participants & Other Collaborating Organizations Individuals who worked on the project: Name Project Role: Researcher Identifier (e.g. ORCID ID): Nearest person month worked: Gabriella D Arcangelo Principal Investigator darcangelo 3 7

Contribution to Project: Funding Support: Name Project Role: Researcher Identifier (e.g. ORCID ID): Nearest person month worked: Contribution to Project: Funding Support: Name Project Role: Researcher Identifier (e.g. ORCID ID): Nearest person month worked: Contribution to Project: Funding Support: Dr. D Arcangelo planned and supervised this study New Jersey State teaching line (Rutgers); this DOD award Beth Crowell Senior lab technician N/A 10 Ms. Crowell managed the NEX-Tsc2 mouse colonies and performed most Western blot analysis This DOD award Avery Zucco Graduate student N/A Changes in active support Partners organizations 6 Mr. Zucco helped performing some Western blot analysis Teaching assistant line; This DOD award 8. SPECIAL REPORTING REQUIREMENTS Since this is a collaborative award, an additional independent report will also be submitted by the Collaborating/Partnering PI (Dr. Anne Anderson, Baylor College of Medicine). 9. APPENDICES: None 8